Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02209012 · ClinicalTrials.gov registry record
Twelve Month Follow-Up of CP0108
A clinical trial, sponsored by DUSA Pharmaceuticals.
- Completed
- Registry status
- 206
- Enrollment target
NCT02209012: Completed study, sponsored by DUSA Pharmaceuticals.
NCT02209012 is a clinical trial that has completed, run by DUSA Pharmaceuticals. The registered enrollment target is 206 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02209012 has completed, sponsored by DUSA Pharmaceuticals.
- COMPLETED
- Registry status
- 206 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the long-term safety and efficacy of Levulan PDT in subjects with multiple actinic keratosis of the upper extremities who received treatment as part of the DUSA CP0108 study.
Primary Outcome
percentage of subjects who had achieved 100% clearance at Visit 6 (Week 12) in CP0108, that have one or more previously treated (as part of CP0108) AK lesion(s) present in the Treatment Area at any visit during CP0108A follow-up
Interventions
- DRUG Aminolevulinic Acid (ALA)
- DRUG Topical Solution Vehicle
- DEVICE BLU-U Blue Light Photodynamic Therapy Illuminator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2014-08 |
| Est. Completion | 2016-04 |
What the finished NCT02209012 record still lists
NCT02209012 is an observational study that tracks outcomes without assigning an intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 3 interventions - of which Aminolevulinic Acid (ALA) is the first listed.
NCT02209012 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02209012 about?
NCT02209012 is a clinical study titled "Twelve Month Follow-Up of CP0108". The purpose of this study is to determine the long-term safety and efficacy of Levulan PDT in subjects with multiple actinic keratosis of the upper extremities who received treatment as part of the DUSA CP0108 study.
What is the current status of trial NCT02209012?
This trial is currently completed. The enrollment target is 206 participants. The study started on 2014-08. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02209012?
The interventions under investigation include: Aminolevulinic Acid (ALA) (DRUG), Topical Solution Vehicle (DRUG), BLU-U Blue Light Photodynamic Therapy Illuminator (DEVICE).
Who is sponsoring clinical trial NCT02209012?
This trial is sponsored by DUSA Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03373968 · 206 participants · Phase 2
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- NCT03550391 · 206 participants · Phase 3
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- NCT04757116 · 206 participants · NA
Post-Market Study to Assess iTind Safety in Comparison to UroLift
- NCT05675865 · 206 participants · NA
Cryoablation for Monomorphic Ventricular Tachycardia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia